Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-term follow-up of RET Y791F carriers in Denmark 1994-2017: A National Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sanne Høxbroe Michaelsen
  • Marie Juul Ornstrup
  • Morten Møller Poulsen
  • Finn Noe Bennedbaek
  • Mette Gaustadnes
  • Maria Rossing
  • Peter Darling
  • Peter Vestergaard
  • Jes Sloth Mathiesen
View graph of relations

BACKGROUND AND OBJECTIVES: Recently, a comprehensive study presented evidence that a long-disputed REarranged during Transfection (RET) variant, RET Y791F, should be classified as nonpathogenic. In spite of this, several subsequently published papers, including the revised American Thyroid Association guidelines for medullary thyroid carcinoma, refer to the variant as pathogenic. This study presents data from a unique national Danish cohort of RET Y791F carriers who have been followed by watchful waiting instead of being subjected to early thyroidectomy, to determine if any carrier shows evidence of multiple endocrine neoplasia 2A (MEN2A) at long-term follow-up.

METHODS: A national cohort of all patients tested for RET mutations in Denmark from September 1994 to October 2017 was searched for carriers of RET Y791F. Medical records and laboratory reports of carriers were reviewed for signs of MEN2A at latest follow-up (medullary thyroid carcinoma, primary hyperparathyroidism, pheochromocytoma, cutaneous lichen amyloidosis, or Hirschsprung's disease).

RESULTS: In total, twenty RET Y791F-carriers were identified, none of whom showed any evidence of MEN2A, despite an age range from 7 to 87 years.

CONCLUSIONS: Our national cohort study of all Danish RET Y791F carriers substantiates the claim that the RET Y791F variant is nonpathogenic.

Original languageEnglish
JournalJournal of Surgical Oncology
Volume119
Issue number6
Pages (from-to)687-693
Number of pages7
ISSN0022-4790
DOIs
Publication statusPublished - May 2019

    Research areas

  • Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Medullary/genetics, Child, Cohort Studies, Denmark/epidemiology, Follow-Up Studies, Genetic Predisposition to Disease/epidemiology, Heterozygote, Humans, Middle Aged, Multiple Endocrine Neoplasia Type 2a/genetics, Mutation, Pheochromocytoma/genetics, Proto-Oncogene Proteins c-ret/genetics, Thyroid Neoplasms/genetics, Young Adult

ID: 58985357